Xiushi Biopharma

Nantong-based company producing peptide APIs by large-scale biosynthesis rather than chemical synthesis, with semaglutide and copper tripeptide-1 as its main products. Holds active US Drug Master Files for retatrutide, semaglutide and tirzepatide API across its Nantong and Rudong entities. No FDA inspection is on record.

Directory assessment: Xiushi Biopharma is listed as a manufacturer in the peptide supply chain, serving Asia markets from China (Nantong). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.